News
- Author:
- Neil Osterweil
Publish date: November 14, 2017
“An obvious next step is to run a clinical trial to test the hypothesis that by modulating the microbiome, you can actually enhance responses to th...
News
- Author:
- Neil Osterweil
Publish date: November 8, 2017
In antitumor immunity and immunotherapy, quality and fitness count.Specifically, the quality and fitness of neoantigens – tumor-specific mutated pe...
News
- Author:
- Neil Osterweil
Publish date: October 28, 2017
Only one in five patients on idelalisib in registration trials remained on the drug after 2 years.
News
- Author:
- Neil Osterweil
Publish date: October 17, 2017
MADRID – Median OS in the ITT population was 8.4 months in the pembrolizumab arm, vs. 7.1 months in the standard-of-care arm.
News
- Author:
- Neil Osterweil
Publish date: October 17, 2017
Tumor levels of the oncogenic protein were predictive of death even among patients considered at low or intermediate risk by a standard prognostic ...
News
- Author:
- Neil Osterweil
Publish date: October 16, 2017
MADRID – The drug sequence matters when it comes to the treatment of advanced or metastatic renal cell carcinoma (mRCC) investigators have found.Th...
News
- Author:
- Neil Osterweil
Publish date: October 16, 2017
MADRID – The 5-year iDFS rate was 90.2% for patients assigned to neratinib, compared with 87.7% for those assigned to placebo.
News
- Author:
- Neil Osterweil
Publish date: October 6, 2017
Three-year progression-free survival was 80% with obinutuzumab, vs. 73.3% with rituximab.
News
- Author:
- Neil Osterweil
Publish date: October 2, 2017
MADRID – Adding cetuximab as either neoadjuvant or adjuvant treatment resulted in significantly worse survival compared with perioperative chemothe...
News
- Author:
- Neil Osterweil
Publish date: September 29, 2017
Patients assigned to robotic-assisted surgery had a total complication rate of 10.4%, compared with 18.8% for patients assigned to laparoscopy and ...
News
- Author:
- Neil Osterweil
Publish date: September 28, 2017
MADRID – Patients with intermediate- or poor-risk advanced clear-cell RCC treated with nivo/ipi did not reach median OS after 32 months’ follow-up....
News
- Author:
- Neil Osterweil
Publish date: September 27, 2017
The rate of 4-year event-free survival was 79% for patients maintained on rituximab vs. 61% for those on observation alone.
News
- Author:
- Neil Osterweil
Publish date: September 25, 2017
MADRID – Complete estrogen blockade showed no improvement in survival over anastrozole alone, although the trial was underpowered.
News
- Author:
- Neil Osterweil
Publish date: September 23, 2017
The nonchemo neoadjuvant regimen offered a slightly higher residual cancer burden prior to surgery, but a significantly better safety profile than ...
News
- Author:
- Neil Osterweil
Publish date: September 21, 2017
MADRID – CT scans show no real advantage over x-rays in overall survival during follow-up after resection, although they may catch other cancers.
